Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Return on Capital Employed (2020 - 2025)

Beam Therapeutics (BEAM) has disclosed Return on Capital Employed for 6 consecutive years, with 0.3% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 14.0% to 0.3% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.3%, a 14.0% increase, with the full-year FY2025 number at 0.32%, up 6.0% from a year prior.
  • Return on Capital Employed was 0.3% for Q4 2025 at Beam Therapeutics, up from 0.4% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.15% in Q1 2024 to a low of 0.65% in Q1 2021.
  • A 5-year average of 0.32% and a median of 0.33% in 2023 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: skyrocketed 43bps in 2022, then decreased -28bps in 2024.
  • Beam Therapeutics' Return on Capital Employed stood at 0.36% in 2021, then rose by 15bps to 0.3% in 2022, then surged by 50bps to 0.15% in 2023, then crashed by -188bps to 0.43% in 2024, then surged by 32bps to 0.3% in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Return on Capital Employed are 0.3% (Q4 2025), 0.4% (Q3 2025), and 0.36% (Q2 2025).